{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:23:15Z","timestamp":1767860595746,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008858.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000}}],"reference-count":86,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008858.pub3","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T18:37:44Z","timestamp":1457203064000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Vaccines for preventing herpes zoster in older adults"],"prefix":"10.1002","author":[{"given":"Anna MZ","family":"Gagliardi","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo; Department of Geriatrics and Gerontology; Rua Professor Francisco de Castro 105 S\u00e3o Paulo S\u00e3o Paulo Brazil 04020-050"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda NG","family":"Andriolo","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Borges Lagoa, 564 cj 63 S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Regina","family":"Torloni","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Borges Lagoa, 564 cj 63 S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo GO","family":"Soares","sequence":"additional","affiliation":[{"name":"Brazilian Cochrane Centre; Alameda Itu 1025\/ 42 S\u00e3o Paulo S\u00e3o Paulo Brazil 01421-001"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD008858.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/514265","article-title":"A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older","volume":"178","author":"Berger","year":"1998","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0264-410X(99)00510-1","article-title":"Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial","volume":"18","author":"Trannoy","year":"2000","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1953-61","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u2265 50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"15","key":"10.1002\/14651858.CD008858.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.vaccine.2014.12.024","article-title":"Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged \u226550 years: a randomised non-inferiority clinical trial","volume":"33","author":"Diez-Domingo","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl","key":"10.1002\/14651858.CD008858.pub3-BIB0006|cit6","first-page":"81-141","article-title":"A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged \u2265 50 years","volume":"4","author":"Diez-Domingo","year":"2013","journal-title":"European Geriatric Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clinical and Vaccine Immunology"},{"issue":"22","key":"10.1002\/14651858.CD008858.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1002\/14651858.CD008858.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/S0264-410X(99)00552-6","article-title":"Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older","volume":"18","author":"Levine","year":"2000","journal-title":"Vaccine"},{"issue":"25","key":"10.1002\/14651858.CD008858.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1016\/j.vaccine.2010.04.003","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster","volume":"28","author":"Mills","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4161\/hv.7.11.17982","article-title":"Safety and tolerability of zoster vaccine in adults \u2265 60 years old","volume":"7","author":"Murray","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"Journal of Infectious Diseases"},{"issue":"22","key":"10.1002\/14651858.CD008858.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/j.1532-5415.2010.03021.x","article-title":"Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults","volume":"58","author":"Schmader","year":"2010","journal-title":"Journal American Geriatrics Society"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1320-8","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.vaccine.2006.10.027","article-title":"Safety and tolerability of a high-potency zoster vaccine in adults \u2265 50 years of age","volume":"25","author":"Tyring","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \u226560 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1-7","DOI":"10.4161\/hv.23412","article-title":"Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax\u00ae) in individuals aged \u2265 70 years. A randomized study of a single dose vs. two different two-dose schedules","volume":"9","author":"Vesikari","year":"2013","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/vim.1994.7.31","article-title":"Immune response to secondary immunization with live or Inactivated VZV vaccine in elderly adults","volume":"7","author":"Hayward","year":"1994","journal-title":"Viral Immunology"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/vim.1996.9.241","article-title":"Varicella zoster virus specific cytotoxicity following secondary immunization with live or killed vaccine","volume":"9","author":"Hayward","year":"1996","journal-title":"Viral Immunology"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub3-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.532-5415.2007.01109.x","article-title":"Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi","volume":"55","author":"Irwin","year":"2007","journal-title":"Journal American Geriatrics Society"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older","volume":"55","author":"Kerzner","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1280-90","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/j.vaccine.2006.11.011","article-title":"Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults","volume":"25","author":"Macaladad","year":"2007","journal-title":"Vaccine"},{"issue":"41","key":"10.1002\/14651858.CD008858.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1016\/j.vaccine.2007.07.051","article-title":"Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine","volume":"25","author":"Patterson-Bartlett","year":"2007","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0028|cit28","unstructured":"'A double-blind, randomised, placebo-controlled, parallel group study to evaluate biomarkers of immunity to varicella zoster virus following immunisation with V212\/heat-treated varicella-zoster virus (VZV) vaccine or with ZOSTAVAX in healthy volunteers' Ongoing study March 2009"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0029|cit29","unstructured":"'Efficacy, safety, and immunogenicity study of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged \u2265 50 years' Ongoing study August 2010"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0030|cit30","unstructured":"'Efficacy, safety and immunogenicity of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged >= 70 years' Ongoing study August 2010"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0031|cit31","unstructured":"'A partially blinded randomised clinical trial to study the immunogenicity and safety of intradermal administration of ZOSTAVAX\u2122 (V211)' Ongoing study September 2011"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0032|cit32","unstructured":"'A phase III double-blinded, randomised, multicenter, controlled study to evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX\u2122 made with an alternative manufacturing process (AMP)' Ongoing study April 2012"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0033|cit33","unstructured":"'Open-label study to evaluate the safety and immunogenicity of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged \u2265 50 years' Ongoing study March 2013"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0034|cit34","unstructured":"'Safety and immunogenicity study of GSK Biologicals' herpes zoster subunit (HZ\/su) vaccine GSK1437173A when administered subcutaneously vs. intramuscularly in adults aged \u2265 50 years' Ongoing study June 2013"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0035|cit35","unstructured":"'Consistency, immunogenicity and safety study of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults \u2265 50 years of age' Ongoing study August 2014"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0036|cit36","unstructured":"'A comparison of the immunogenicity and descriptive safety of a live attenuated herpes zoster vaccine and the GSK herpes zoster recombinant HZ\/su candidate vaccine in 50 to 59 year old and 70 to 85 year old vaccine recipients' Ongoing study May 2014"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0037|cit37","unstructured":"'A phase III, double-blind, lot-to-lot consistency clinical trial to evaluate the safety, tolerability and immunogenicity of V212 in healthy adults' Ongoing study July 2014"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0038|cit38","unstructured":"'Safety and immunogenicity study of live attenuated vaccine against herpes zoster in Chinese adults aged 50 years and older' Ongoing study November 2015"},{"issue":"22","key":"10.1002\/14651858.CD008858.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Ageing, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.4049\/jimmunol.137.4.1346","article-title":"Immunity to varicella-zoster viral glycoproteins, gp I (gp 90\/58) and gp III (gp 118), and to a nonglycosylated protein, p 170","volume":"137","author":"Arvin","year":"1986","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clinical Microbiology Reviews"},{"issue":"7454","key":"10.1002\/14651858.CD008858.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"GRADE Working Group. Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","article-title":"Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents","volume":"4","author":"Baldridge","year":"2004","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jdermsci.2006.11.004","article-title":"Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea","volume":"45","author":"Cho","year":"2007","journal-title":"Journal of Dermatological Science"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcv.2010.01.003","article-title":"Disease burden of herpes zoster in Korea","volume":"47","author":"Choi","year":"2010","journal-title":"Journal of Clinical Virology"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0046|cit46","first-page":"2773","article-title":"Varicella-zoster virus replication, pathogenesis, and management","volume-title":"Fields\u2019 Virology","author":"Cohen","year":"2007"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub3-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"Journal of Pain"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub3-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.7326\/0003-4819-89-3-375","article-title":"Herpes zoster-varicella infections in immunosuppressed patients","volume":"89","author":"Dolin","year":"1978","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pain.2008.12.022","article-title":"A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster","volume":"142","author":"Dworkin","year":"2009","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/jmv.21748","article-title":"No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia","volume":"82","author":"Gatti","year":"2010","journal-title":"Journal of Medical Virology"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"635-45","DOI":"10.1056\/NEJM200003023420906","article-title":"Neurologic complications of the reactivation of varicella zoster virus","volume":"342","author":"Gilden","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice: herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0053|cit53","unstructured":"McMaster University (developed by Evidence Prime, Inc.) GRADEpro GDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org] 2015"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.7326\/ACPJC-2006-144-1-A08","article-title":"An emerging consensus on grading recommendations?","volume":"144","author":"Guyatt","year":"2006","journal-title":"ACP Journal Club"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/00365540110077218","article-title":"Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster","volume":"34","author":"Haanpaa","year":"2002","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s15010-007-6347-x","article-title":"Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel","volume":"36","author":"Heymann","year":"2008","journal-title":"Infection"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archderm.144.5.603","article-title":"Family history as a risk factor for herpes zoster: a case-control study","volume":"144","author":"Hicks","year":"2008","journal-title":"Archives of Dermatology"},{"issue":"7414","key":"10.1002\/14651858.CD008858.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0060|cit60","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/003591576505800106","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proceedings of the Royal Society of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and post herpetic neuralgia in older adults","volume":"145","author":"Hornberger","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2340\/00015555-0729","article-title":"Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006","volume":"89","author":"Jih","year":"2009","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"342-8","DOI":"10.1086\/421942","article-title":"Acute pain in herpes zoster and its impact on health-related quality of life","volume":"39","author":"Katz","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molinacortex","volume":"146","author":"Kensil","year":"1991","journal-title":"Journal of Immunology"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PLoS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0300-8932(97)73190-7","article-title":"Investigation methods in clinical cardiology (IV) clinical measurements in cardiology: validity and errors of measurement","volume":"50","author":"Latour","year":"1997","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub3-BIB0068|cit68","first-page":"681","article-title":"Severe autoimmune adverse events post herpes zoster vaccine: a case-control study of adverse events in a national database","volume":"14","author":"Lai","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub3-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1046\/j.1365-3156.1998.00316.x","article-title":"Review of varicella zoster soroepidemiology in India and South-East Asia","volume":"3","author":"Lee","year":"1998","journal-title":"Tropical Medicine & International Health"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0070|cit70","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD008858.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1212\/WNL.45.12_Suppl_8.S52","article-title":"Herpes zoster and quality of life: a self-limited disease with severe impact","volume":"45","author":"Lydick","year":"1995","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0072|cit72","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545313.038","article-title":"Pathogenesis and the disease consequences of primary infection","volume-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","author":"Moffat","year":"2007"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/14656560902808502","article-title":"The treatment of varicella-zoster virus infection and its complications","volume":"10","author":"Partridge","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"14","key":"10.1002\/14651858.CD008858.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1263-76","DOI":"10.1016\/0264-410X(95)00011-O","article-title":"Adjuvants for human vaccines - current status, problems and future prospects","volume":"13","author":"Rajesh","year":"1995","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0075|cit75","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/651078","article-title":"Increasing incidence of herpes zoster among veterans","volume":"50","author":"Rimland","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4065\/84.3.274","article-title":"Herpes zoster (shingles) and postherpetic neuralgia","volume":"84","author":"Sampathkumar","year":"2009","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/10489140-000000000-00000","article-title":"Zoster vaccine (Zostavax\u00ae) a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults","volume":"27","author":"Sanford","year":"2010","journal-title":"Drugs and Aging"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","article-title":"Herpes zoster pain and discomfort on functional status and quality of life in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clinical Journal of Pain"},{"issue":"Suppl","key":"10.1002\/14651858.CD008858.pub3-BIB0080|cit80","first-page":"207-15","article-title":"The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine","volume":"197","author":"Schmader","year":"2008","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0081|cit81","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008858.pub3-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1128\/CVI.00407-08","article-title":"Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older","volume":"16","author":"Sutradhar","year":"2009","journal-title":"Clinical and Vaccine Immunology"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008858.pub3-BIB0084|cit84","first-page":"2","article-title":"The burden of herpes zoster and postherpetic neuralgia in the United States","volume":"107","author":"Weaver","year":"2007","journal-title":"Journal of the American Osteopathic Association"},{"issue":"12","key":"10.1002\/14651858.CD008858.pub3-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008858","article-title":"Vaccines for preventing herpes zoster in older adults","author":"Gagliardi","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub3-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008858.pub2","article-title":"Vaccines for preventing herpes zoster in older adults","author":"Gagliardi","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008858.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008858.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T04:03:32Z","timestamp":1692245012000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008858.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Acute Respiratory Infections Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":86,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008858.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD008858.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}